Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (617)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00185523 | Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) | terminated | — | 88 | Stanford UniversityOTHER | 1 | Jun 16, 2016 | clinicaltrials |
| NCT02029417 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2016 | clinicaltrials |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | terminated | Phase 1 / Phase 2 | 4 | Baylor College of MedicineOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT02221505 | Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Novartis PharmaceuticalsINDUSTRY | 4 | Apr 5, 2016 | clinicaltrials |
| NCT01573247 | Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 25 | Akinion Pharmaceuticals ABINDUSTRY | 4 | Mar 25, 2016 | clinicaltrials |
| NCT01455025 | Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia(PRIMAL) | terminated | Phase 1 | 11 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | terminated | Phase 1 | 16 | Erimos PharmaceuticalsINDUSTRY | 1 | Feb 23, 2016 | clinicaltrials |
| NCT00660036 | Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia | terminated | Phase 1 | 5 | University of PittsburghOTHER | 1 | Jan 15, 2016 | clinicaltrials |
| NCT00866281 | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia | terminated | Phase 1 / Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 22, 2015 | clinicaltrials |
| NCT01169753 | Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients | terminated | N/A | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 8, 2015 | clinicaltrials |
| NCT02034227 | Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | SpirogenINDUSTRY | 1 | Nov 23, 2015 | clinicaltrials |
| NCT00860535 | Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED) | terminated | Phase 1 | 9 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 30, 2015 | clinicaltrials |
| NCT01794169 | Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML | terminated | Phase 2 | 130 | Karolinska University HospitalOTHER | 1 | Sep 22, 2015 | clinicaltrials |
| NCT00464113 | Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia | terminated | Phase 1 | 49 | ExelixisINDUSTRY | 1 | Aug 21, 2015 | clinicaltrials |
| NCT01260714 | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia | terminated | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2015 | clinicaltrials |
| NCT01489722 | Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients | terminated | Phase 1 | 55 | AstraZenecaINDUSTRY | 2 | Aug 11, 2015 | clinicaltrials |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | terminated | Phase 1 | 2 | Celgene CorporationINDUSTRY | 1 | Jul 28, 2015 | clinicaltrials |
| NCT00374296 | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease | terminated | Phase 2 | 35 | Mirati Therapeutics Inc.INDUSTRY | 2 | Jul 1, 2015 | clinicaltrials |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | terminated | Phase 1 | 11 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01222143 | Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 12 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01521936 | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy | terminated | Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00100152 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) | terminated | Phase 1 | 50 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 27, 2015 | clinicaltrials |
| NCT01130688 | Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. | terminated | Phase 1 | 2 | University of Massachusetts, WorcesterOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT00666497 | Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 6 | Mirati Therapeutics Inc.INDUSTRY | 3 | May 8, 2015 | clinicaltrials |
| NCT00669890 | Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML(High Risk) | terminated | Phase 1 | 12 | New York Medical CollegeOTHER | 1 | Apr 22, 2015 | clinicaltrials |
| NCT01203228 | Dose-reduced Versus Standard Conditioning in MDS/sAML(RICMAC) | terminated | Phase 3 | 129 | European Society for Blood and Marrow TransplantationNETWORK | 4 | Apr 3, 2015 | clinicaltrials |
| NCT00500006 | A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) | terminated | Phase 1 | 3 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 30, 2015 | clinicaltrials |
| NCT00114959 | Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) | terminated | Phase 2 | 15 | ChemGenex PharmaceuticalsINDUSTRY | 1 | Jan 15, 2015 | clinicaltrials |
| NCT00907582 | ASCT for Relapsed APL After Molecular Remission | terminated | Phase 2 | 5 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT01650805 | Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) | terminated | Phase 3 | 307 | Ariad PharmaceuticalsINDUSTRY | 24 | Nov 17, 2014 | clinicaltrials |
| NCT00594308 | In-Vivo Activated T-Cell Depletion to Prevent GVHD | terminated | N/A | 10 | Indiana UniversityOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00593645 | Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation | terminated | Phase 2 | 7 | Washington University School of MedicineOTHER | 1 | Sep 12, 2014 | clinicaltrials |
| NCT00184054 | Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia | terminated | Phase 2 | 11 | University of Southern CaliforniaOTHER | 1 | Jul 25, 2014 | clinicaltrials |
| NCT00415909 | TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2014 | clinicaltrials |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 2 | May 1, 2014 | clinicaltrials |
| NCT01193400 | Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years | terminated | Phase 2 | 75 | PETHEMA FoundationOTHER | 1 | Apr 7, 2014 | clinicaltrials |
| NCT01198054 | LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) | terminated | Phase 4 | 4 | PETHEMA FoundationOTHER | 1 | Apr 7, 2014 | clinicaltrials |
| NCT01655875 | AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia(BMTAMD3100) | terminated | Phase 1 | 1 | Emory UniversityOTHER | 1 | Apr 7, 2014 | clinicaltrials |
| NCT01426334 | Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate | terminated | Phase 1 | 4 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00923234 | Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes(AZALE) | terminated | Phase 1 | — | Technische Universität DresdenOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00672152 | A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation(WT-1) | terminated | Phase 1 | 8 | Michael Morse, MDOTHER | 1 | Dec 10, 2013 | clinicaltrials |
| NCT00967525 | Intraosseous Infusion of Unrelated Cord Blood Grafts | terminated | N/A | 5 | Emory UniversityOTHER | 1 | Nov 27, 2013 | clinicaltrials |
| NCT00814983 | Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft | terminated | Phase 1 / Phase 2 | 15 | Duke UniversityOTHER | 0 | Nov 25, 2013 | clinicaltrials |
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | terminated | Phase 2 | 1 | Texas Oncology Cancer CenterINDUSTRY | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00985530 | Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia | terminated | Phase 1 | 4 | Northwestern UniversityOTHER | 1 | Oct 30, 2013 | clinicaltrials |
| NCT00049582 | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00301769 | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia | terminated | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00720850 | Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)(LENAMAINT) | terminated | Phase 2 | 10 | Technische Universität DresdenOTHER | 1 | Sep 27, 2013 | clinicaltrials |
| NCT01159301 | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jun 16, 2016source: clinicaltrials